In brief
TE BioS introduced CorriX®, a dietary supplement based on a patented bacterial strain, at the 21st World Korean Business Convention. The company says German clinical trials involving 140 participants found that 75% of participants who regularly took the product experienced increased production of Tfa IgM antibodies. TE BioS also reports that CorriX has received U.S. FDA GRAS notification and EU Novel Food certification, and that the strain has patents in 32 countries. The company plans to pursue markets in the United States, Europe and Japan. The release also describes a Nature Microbiology review discussing B. xylanisolvens and potential links between TFα antibodies and cancer immune surveillance; it does not establish CorriX as a cancer treatment. TE BioS says the product is part of its broader work on immune health.
Key takeaways
- TE BioS introduced its CorriX dietary supplement at the 21st World Korean Business Convention.
- The company reports German clinical trial results involving 140 participants, with 75% experiencing increased Tfa IgM antibody production.
- TE BioS says CorriX has U.S. FDA GRAS notification and EU Novel Food certification.
- The company plans to expand CorriX into the United States, Europe and Japan.
- The release states the product’s bacterial strain is patented in 32 countries.
CorriX® is a Dietary Supplement Made From a Unique Combination of a Patented Strain to Enhance Immune Health
Republic of Korea, September 16, 2023 -- TE BioS, a leader in bioscience innovations, is excited to introduce 'CorriX®,' a dietary supplement proven to support immune health, at the 21st World Korean Business Convention. Based on a patented bacterial strain solely owned by the company, CorriX® has undergone rigorous clinical trials in Germany involving 140 participants to prove its efficacy. Not only has it received US FDA GRAS (Generally Recognized as Safe) and EU ESFA Novel Food certifications, affirming its safety, but it is also featured as a Next Generation Probiotics in Nature Microbiology. With this product, TE BioS has set ambitious plans to broaden its product line, CorriX®, into the United States, Europe, and Japan, solidifying its role as a global immune health brand.
Founded in 2009, TE BioS aims to create value through human-centric technology and innovation, and the release of CorriX® aligns perfectly with that mission. CorriX® has already been patented in 32 countries around the world, including the U.S. and EU, which makes it a highly competitive and promising entrant in the global dietary supplements market. Its introduction at the 21st World Korean Business Convention marks the beginning of its global expansion, with an initial focus on penetrating markets in the United States, Europe, and Japan.
The effectiveness of CorriX® as an immune supporter has been demonstrated through a robust clinical trial conducted in Germany.
Clinical trials have shown that 75% of participants who regularly took CorriX® experienced induced production of Tfa IgM antibodies, which serve as immune support and immune surveillance.
This ground-breaking product stands out not only for its proven efficacy but also for its potential to evolve into a pharmaceutical product with anti-cancer properties, as hinted at in its feature in Nature Microbiology.
The review paper published in Nature Microbiology introduced the value of B.xylanisolvens as a Next Generation Probiotics (NGP). The authors speculated that an increase in TFα antibodies would promote a more robust response to cancer and thus ameliorate the host’s own cancer immune surveillance system.
With the dietary supplement market continually growing, CorriX® aims to fill a void by providing a product that is not only scientifically proven to be effective but also safe, as confirmed by its FDA GRAS notification and EU ESFA Novel Food certification.
CorriX® is a dietary supplement with a unique combination of a patented bacterial strain that synergize to enhance immune health. It's the embodiment of TE BioS' scientific approach to utilizing beneficial bacteria that have coexisted with the human body to support immune health. By using a proprietary culturing and blend, TE BioS has crafted a product with immense promise, backed by scientific rigor and certifications, and looks forward to seeing how CorriX® will improve lives globally.
TE BioS invites inquiries about CorriX® and is confident that this revolutionary product marks the beginning of a new chapter in immune health solutions worldwide. The company's unique culturing and blend of humanitarian focus and scientific innovation make it an exciting contributor to the future of global health. As it gears up for its participation in the 21st World Korean Business Convention, TE BioS is poised to make significant contributions to immune health globally.
Contact Info:
Name: Sean Park
Email: Send Email
Organization: TE BioS
Address: Republic of Korea
Phone: +82 43-218-4944
Website: http://tebios.com
If you detect any issues, problems, or errors in this press release content, kindly contact [email protected] to notify us (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). We will respond and rectify the situation in the next 8 hours.
At a glance
- Company
- TE BioS
- Announcement
- Expansion
- Location
- Republic of Korea
Key figures
- Participants in German clinical trials
- 140
- Participants with induced Tfa IgM antibody production
- 75%
- Countries where the strain is patented
- 32
People
- Sean Park
